INCYTE CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.08 USD | +0.99% |
|
+0.74% | -17.14% |
| 09:52pm | Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained | MT |
| 03:42pm | Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
Chart calendar Incyte Corporation
52843d30ab04fff7bd4ebf0f.l_ZTtW704T9gN2M8wSFsr89y0IoabuZFIuv7L6_uFE0.39tk4Q-brwkRWVZRmBUZnYgeo-ROK4d8EL2vXeyYLA7koDb0JYysUVYHBA~3fd73209943f78e01a88279d6c3d2f92
Upcoming events on Incyte Corporation
Past events on Incyte Corporation
| Today 08:00 am | Q1 2024 Earnings Call |
| Today 07:00 am | Q1 2024 Earnings Release |
| 2024-04-23 08:00 am | Acquisition of Escient Pharmaceuticals by Incyte Corp Call |
| 2024-03-11 12:00 pm | American Academy of Dermatology Meeting |
| 2024-03-10 04:10 pm | American Academy of Dermatology Meeting |
| 2024-03-10 04:00 pm | American Academy of Dermatology Meeting |
| 2024-03-08 04:10 pm | American Academy of Dermatology Meeting |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #53971 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #53962 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #50342 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #454168 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #54147 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #54025 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #53107 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #53102 |
| 2024-03-07 | American Academy of Dermatology Meeting - Abstract #49439 |
| 2024-03-04 09:50 am | TD Cowen Health Care Conference |
| 2024-02-13 08:00 am | Q4 2023 Earnings Call |
| 2024-02-13 07:00 am | Q4 2023 Earnings Release |
| 2024-01-08 10:30 am | JPMorgan Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2 159 2 157 0.1% | 2 667 2 534 5.25% | 2 986 2 925 2.09% | 3 395 3 343 1.55% | 3 696 3 689 0.17% | 4 136 |
|
EBITDA Million USD | Released Forecast Spread | 457 480 -4.86% | -212 -267 20.55% | 644 752 -14.45% | 598 679 -11.94% | 703 724 -2.83% | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 402 409 -1.81% | -264 -302 12.57% | 586 631 -7.19% | 579 667 -13.15% | 621 720 -13.86% | 1 158 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 487 452 7.75% | -232 -268 13.2% | 570 615 -7.27% | 529 554 -4.5% | 834 817 2.07% | 1 058 |
|
Net income Million USD | Released Forecast Spread | 447 418 7.01% | -296 -332 10.84% | 949 518 83.28% | 341 380 -10.27% | 598 596 0.28% | 793 |
|
EPS USD | Released Forecast Spread | 2,05 1,89 8.73% | -1,36 -1,51 10.12% | 4,27 2,34 82.81% | 1,52 1,66 -8.5% | 2,65 2,63 0.69% | 3,40 |
| Announcement Date | 13/02/20 | 09/02/21 | 08/02/22 | 07/02/23 | 13/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 863 814 6.04% | 733 754 -2.69% | 911 818 11.38% | 823 845 -2.52% | 927 880 5.28% | 809 859 -5.81% | 955 910 4.86% | 919 963 -4.61% | 1 013 1 003 0.99% | 881 925 -4.73% | 1 023 | 1 051 | 1 112 | 1 072 |
|
EBITDA Million USD | Released Forecast Spread | 126 201 -37.43% | 271 200 35.75% | 155 201 -23.04% | 138 128 7.67% | 214 203 5.26% | 236 | 213 | |||||||
|
EBIT Million USD | Released Forecast Spread | 111 153 -27.62% | 117 122 -4.37% | 254 164 55.16% | 138 169 -17.94% | 70,1 101 -30.8% | 24,8 161 -84.61% | 194 173 11.98% | 215 212 1.27% | 187 244 -23.39% | 91,9 199 -53.78% | 284 | 306 | 312 | 342 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 120 164 -26.91% | 70,5 131 -46.01% | 229 162 41.59% | 149 146 2.01% | 80,6 76,6 5.21% | 51,9 164 -68.45% | 278 188 47.49% | 234 236 -0.86% | 271 275 -1.35% | 236 198 19.34% | 284 | 288 | 331 | |
|
Net income Million USD | Released Forecast Spread | 564 137 310.43% | 38,0 93,6 -59.42% | 161 121 33.83% | 113 108 4.54% | 28,5 61,1 -53.41% | 21,7 112 -80.64% | 204 142 43.46% | 171 179 -4.11% | 201 208 -3.36% | 170 132 28.79% | 145 | 177 | 260 | |
|
EPS USD | Released Forecast Spread | 2,54 0,63 305.76% | 0,17 0,40 -57.76% | 0,72 0,54 33.08% | 0,50 0,49 1.35% | 0,13 0,25 -48.19% | 0,10 0,52 -80.61% | 0,90 0,64 40.9% | 0,76 0,82 -7.21% | 0,89 0,91 -2.22% | 0,75 0,59 27.07% | 0,64 | 0,78 | 1,14 | |
| Announcement Date | 08/02/22 | 03/05/22 | 02/08/22 | 01/11/22 | 07/02/23 | 02/05/23 | 01/08/23 | 31/10/23 | 13/02/24 | 30/04/24 | - | - | - | - |
| 2024-05-01 | BRIDGEBIO PHARMA, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-01 | TWIST BIOSCIENCE CORPORATION: Q2 2024 Earnings Release |
| 2024-05-01 | SK BIOSCIENCE CO.,LTD.: Q1 2024 Earnings Release |
| 2024-05-06 07:00 am | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-06 | BIOTEST AG: Q1 2024 Earnings Release |
| 2024-05-06 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | REVANCE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 2024-05-07 02:00 am | BIOGAIA AB: Q1 2024 Earnings Release |
| 2024-05-07 | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Incyte Corporation
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- INCY Stock
- Calendar Incyte Corporation
